Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Solas

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Pharmacogenomics|September 6, 2019
Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiencyCrescent C Gbeto, Sylvie Quaranta, Roxane Mari, et al.
Fundamental & Clinical Pharmacology|July 1, 2020
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatmentsFlorian Lemaitre, Caroline Solas, Matthieu Grégoire, et al.
AIDS (London, England)|April 26, 2017
Neuropsychiatric adverse effects on dolutegravir: an emerging concern in EuropeAmélie Menard, Clementine Montagnac, Caroline Solas, et al.
International Journal of Legal Medicine|December 20, 2023
Severe 25E-NBOH intoxication associated with MDPHP intake: a case report, metabolism study, and literature reviewRomain Pelletier, Thomas Gicquel, Julien Carvelli, et al.
Journal of Virus Eradication|July 28, 2018
Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global healthChristina Psomas, Sabine Kinloch, Caroline Sabin, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2012
Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIVStéphanie Dominguez, Jade Ghosn, Bruno Cassard, et al.
European Journal of Clinical Pharmacology|January 28, 2018
Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabineNadège Néant, Florence Gattacceca, Minh Patrick Lê, et al.
The Journal of Antimicrobial Chemotherapy|July 10, 2012
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitorMinh Patrick Lê, Caroline Solas, Rodolphe Garraffo, et al.
Antiviral Therapy|April 1, 2017
Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patientsAudrey Taton, Philippe Colson, Catherine Dhiver, et al.
British Journal of Clinical Pharmacology|May 7, 2020
Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patientsNadège Néant, Minh Patrick Lê, Naïm Bouazza, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Pharmacogenomics|September 6, 2019
Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiencyCrescent C Gbeto, Sylvie Quaranta, Roxane Mari, et al.
Fundamental & Clinical Pharmacology|July 1, 2020
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatmentsFlorian Lemaitre, Caroline Solas, Matthieu Grégoire, et al.
AIDS (London, England)|April 26, 2017
Neuropsychiatric adverse effects on dolutegravir: an emerging concern in EuropeAmélie Menard, Clementine Montagnac, Caroline Solas, et al.
International Journal of Legal Medicine|December 20, 2023
Severe 25E-NBOH intoxication associated with MDPHP intake: a case report, metabolism study, and literature reviewRomain Pelletier, Thomas Gicquel, Julien Carvelli, et al.
Journal of Virus Eradication|July 28, 2018
Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global healthChristina Psomas, Sabine Kinloch, Caroline Sabin, et al.
The Journal of Antimicrobial Chemotherapy|March 8, 2012
Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIVStéphanie Dominguez, Jade Ghosn, Bruno Cassard, et al.
European Journal of Clinical Pharmacology|January 28, 2018
Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabineNadège Néant, Florence Gattacceca, Minh Patrick Lê, et al.
The Journal of Antimicrobial Chemotherapy|July 10, 2012
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitorMinh Patrick Lê, Caroline Solas, Rodolphe Garraffo, et al.
Antiviral Therapy|April 1, 2017
Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patientsAudrey Taton, Philippe Colson, Catherine Dhiver, et al.
British Journal of Clinical Pharmacology|May 7, 2020
Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patientsNadège Néant, Minh Patrick Lê, Naïm Bouazza, et al.
Pageof 13